Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

Authors Piet Geusens, Willem Lems

Published Date April 2008 Volume 2008:4(2) Pages 337—344

DOI http://dx.doi.org/10.2147/TCRM.S1209

Published 21 April 2008

Piet Geusens1, Willem Lems2

1Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands and Biomedical Research Institute, University Hasselt, Belgium; 2Vrije Universiteit Medical Centre, Department of Rheumatology, Amsterdam, the Netherlands

Abstract: Lumiracoxib is a COX2 inhibitor that is highly selective, is more effective than placebo on pain in osteoarthritis (OA), with similar analgesic and anti-inflammatory effects as non-selective NSAIDs and the selective COX2 inhibitor celecoxib, has a lower incidence of upper gastrointestinal (GI) side effects in patients not taking aspirin, and a similar incidence of cardiovascular (CV) side effects compared to naproxen or ibuprofen. In the context of earlier guidelines and taking into account the GI and CV safety results of the TARGET study, lumiracoxib had secured European Medicines Agency (EMEA) approval with as indication symptomatic treatment of OA as well as short-term management of acute pain associated with primary dysmenorrhea and following orthopedic or dental surgery. In the complex clinical context of efficiency and safety of selective and non-selective COX inhibitors, its prescription and use should be based on the risk and safety profile of the patient. In addition, there is further need for long-term GI and CV safety studies and general post-marketing safety on its use in daily practice. Meanwhile, at the time of submission of this manuscript, the EMEA has withdrawn lumiracoxib throughout Europe because of the risk of serious side effects affecting the liver.

Keywords: lumiracoxib, NSAIDs, COX2 inhibitors, gastro-intestinal and cardiovascular safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Prevalence and correlates of suicide ideation in patients with COPD: a mixed methods study

Fleehart S, Fan VS, Nguyen HQ, Lee J, Kohen R, Herting JR, Matute-Bello G, Adams SG, Pagalilauan G, Borson S

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1321-1329

Published Date: 4 December 2014

Surface characteristics of and in vitro behavior of osteoblast-like cells on titanium with nanotopography prepared by high-energy shot peening

Deng Z, Yin B, Li W, Liu J, Yang J, Zheng T, Zhang D, Yu H, Liu X, Ma J

International Journal of Nanomedicine 2014, 9:5565-5573

Published Date: 28 November 2014

Proposed criteria for schizophrenia remission

AlAqeel B

Neuropsychiatric Disease and Treatment 2014, 10:619-623

Published Date: 16 April 2014

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease

Kano O, Urita Y, Ito H, Takazawa T, Kawase Y, Murata K, Hirayama T, Miura K, Ishikawa Y, Kiyozuka T, Aoyagi J, Iwasaki Y

Neuropsychiatric Disease and Treatment 2013, 9:1411-1415

Published Date: 18 September 2013

Aggressive behavior, cognitive impairment, and depressive symptoms in elderly subjects

Margari F, Sicolo M, Spinelli L, Mastroianni F, Pastore A, Craig F, Petruzzelli MG

Neuropsychiatric Disease and Treatment 2012, 8:347-353

Published Date: 1 August 2012

The noradrenergic symptom cluster: clinical expression and neuropharmacology

Blier P, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:15-20

Published Date: 3 June 2011

Depression and smoking cessation: Does the evidence support psychiatric practice?

Anna Lembke, Kenasha Johnson, Charles DeBattista

Neuropsychiatric Disease and Treatment 2007, 3:487-493

Published Date: 8 October 2007

Conversion disorder: towards a neurobiological understanding

Samuel B Harvey, Biba R Stanton, Anthony S David

Neuropsychiatric Disease and Treatment 2006, 2:13-20

Published Date: 18 February 2006